Fox Chase Cancer Center News

PHILADELPHIA (April 25, 2022)— Fifty-two Fox Chase Cancer Center physicians have been named to Philadelphia magazine’s “Top Doctors” list for 2022. Physicians on the list were nominated by a national survey of their professional peers.

PHILADELPHIA (April 20, 2022)—In a study published today in the prestigious journal Nature Communications, researchers at Fox Chase Cancer Center defined 11 subsets of cells found in the esophagus of mice, information that could potentially help clinicians diagnose or treat certain types of cancer.

PHILADELPHIA (April 18, 2022)—Nurses at Fox Chase Cancer Center successfully implemented an electronic medical record tool to improve compliance documentation for patients taking oral chemotherapy drugs.

Philadelphia, PA and Washington, DC. (April 13, 2022) — Cancer Study Group, LLC, a company that works with employer and union health plans to guide their patients through cancer, is partnering with Fox Chase Cancer Center to provide patients fast, dedicated access to sub-specialized care.

PHILADELPHIA (April 4, 2022)—Nonsmokers with the two most common types of driver-gene mutated lung cancer have higher levels of the estrogen derivative 4-OHE, according to early data from researchers at Fox Chase Cancer Center, which will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 on April 8-13, 2022.

PHILADELPHIA (April 4, 2022)— During the American Association for Cancer Research (AACR) Annual Meeting 2022 on April 8-13, 2022, researchers from the lab of Philip Abbosh, MD, PhD, an assistant professor in the Molecular Therapeutics research program at Fox Chase Cancer Center, will present findings from recent studies.

PHILADELPHIA (April 4, 2022)—Elizabeth Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology and professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, has been appointed Deputy Director.

PHILADELPHIA (March 31, 2022)—Researchers at Fox Chase Cancer Center have published a new study that identifies several characteristics of papillary renal neoplasm with reverse polarity (PRNRP), a neoplasm that may simply be monitored rather than removing it through surgery.